Interferon alpha receptors are important for antiproliferative effect of interferon-α against human hepatocellular carcinoma cells

Hepatology Research

Volumn 37, Issue 1, 2007, Pages 77-83

  Damdinsuren, Bazarragchaa ^a   Nagano, Hiroaki ^a   Wada, Hiroshi ^a   Noda, Takehiro ^a   Natsag, Javzandulam ^a   Marubashi, Shigeru ^a   Miyamoto, Atsushi ^a   Takeda, Yutaka ^a   Umeshita, Koji ^a   Doki, Yuichiro ^a   Dono, Keizo ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiproliferative effect; Hepatocellular carcinoma; Interferon; Interferon alpha receptor; Short interfering RNA

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL MEMBRANE; CELL STRAIN HEPG2; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 33947159315     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00007.x     Document Type: Article

References (28)

1. Sakon M, Nagano H, Dono K et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002 ; 94: 435-42.
2. Patt YZ, Hassan MM, Lozano RD et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003 ; 21: 421-7.
3. Nagano H, Sakon M, Eguchi H et al. Hepatic resection followed by IFN-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 2006 ; (in press).
4. Obi S, Yoshida H, Toune R et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006 ; 106: 1990-7.
5. Ota H, Nagano H, Sakon M et al. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005 ; 93: 557-64.
6. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999 ; 29: 62-7.
7. Lai CL, Lau JY, Wu PC et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial. Hepatology 1993 ; 17: 389-94.
8. Llovet JM, Sala M, Castells L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000 ; 31: 54-8.
9. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998 ; 67: 227-64.
10. Sangfelt O, Strander H. Apoptosis and cell growth inhibition as antitumor effector functions of interferons. Med Oncol 2001 ; 18: 3-14.
11. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: Structure, function, and evolution of a family business. J Interferon Cytokine Res 1999 ; 19: 1069-98.
12. Yano H, Iemura A, Haramaki M et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999 ; 29: 1708-17.
13. Damdinsuren B, Nagano H, Sakon M et al. Interferon-beta is more potent than interferon-alpha in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 2003 ; 10: 1184-90.
14. Eguchi H, Nagano H, Yamamoto H et al. Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with upregulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000 ; 6: 2881-90.
15. Kondo M, Nagano H, Wada H et al. Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. Clin Cancer Res 2005 ; 11: 1277-86.
16. Yamamoto T, Nagano H, Sakon M et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clin Cancer Res 2004 ; 10: 7884-95.
17. Damdinsuren B, Nagano H, Kondo M et al. TGF-beta1-induced cell growth arrest and partial differentiation is related to the suppression of Id1 in human hepatoma cells. Oncol Rep 2006 ; 15: 401-8.
18. Ogawa M, Yamamoto H, Nagano H et al. Hepatic expression of ANG2 RNA in metastatic colorectal cancer. Hepatology 2004 ; 39: 528-39.
19. Toth M, Gervasi DC, Fridman R. Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells. Cancer Res 1997 ; 57: 3159-67.
20. Domanski P, Witte M, Kellum M et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J Biol Chem 1995 ; 270: 21606-11.
21. Kotenko SV, Izotova LS, Mirochnitchenko OV, Lee C, Pestka S. The intracellular domain of interferon-alpha receptor 2c (IFN-alphaR2c) chain is responsible for Stat activation. Proc Natl Acad Sci USA 1999 ; 96: 5007-12.
22. Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, Uchida K. Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim Biophys Acta 2005 ; 1745: 401-10.
23. Leung TW, Tang AM, Zee B et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002 ; 94: 421-7.
24. Kaneko S, Urabe T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. Oncology 2002 ; 62 (Suppl 1): 69-73.
25. Kondo M, Nagano H, Sakon M et al. Expression of interferon alpha/beta receptor in human hepatocellular carcinoma. Int J Oncol 2000 ; 17: 83-8.
26. Takayama A, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression of Hu-IFN-alphaR2 chain of type I interferon receptor in human hepatocellular carcinoma and non-cancerous tissues. Int J Mol Med 2000 ; 6: 621-7.
27. Wagner TC, Velichko S, Chesney SK et al. Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int J Cancer 2004 ; 111: 32-42.
28. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: Clinical targets. Semin Cancer Biol 2000 ; 10: 125-44.